Currently, BioNexus Gene Lab Corp’s (BGLC) stock is trading at $12.4, marking a gain of 303.91% from last night’s close. At this price, the stock is 47.62% below its 52-week high of $8.40 and 517.90% above its 52-week low of $2.01. Based on the past 30-day period, the stock price is -9.55% below the high and +442.69% above the low.
The 200-day Simple moving average is often placed more emphasis on by traders because of daily price changes. Investors will use the SMA-200 in different situations in trading activity as a key indicator to determine their support and resistance levels, and at the moment, BGLC’s SMA-200 is $3.35.
As well, it is important to consider BGLC stock ratios such as price-to-sales, which is currently 2.41.BGLC’s price to book ratio for the most recent quarter was 2.87, resulting in an 6.19 price to cash per share for the period.
How does BioNexus Gene Lab Corp (BGLC) stock rate among analysts? Buy, sell, or hold?
The key to trading is to concentrate on the future rather than on the past. During uncertain times, it can be hard to make decisions. The analysts who understand how a market works are usually the most accurate at forecasting its future. The ratings are commonly aggregated into a single number between 1 and 5. Buy or strong buy is scored 5, outperform is scored 4, hold is scored 3, underperform is scored 2 and strong sell is 1.
BioNexus Gene Lab Corp (BGLC): Earnings History
If we examine BioNexus Gene Lab Corp’s recent earnings history, in the last quarter ended on Next Year (1970), it posted adjusted earnings per share of $0, slashing the consensus of $0. In other words, it topped the consensus by $0, resulting in a 0 surprise. In the 3 months period before the previous quarter which was closed on Next Year (1970), the stock recorded adjusted earnings per share of $0 in contrast with the Outlook of $0. That was a difference of $0 and a surprise of 0.
BioNexus Gene Lab Corp (NASDAQ: BGLC) Ownership Details
I will give a breakdown of the key shareholders in BioNexus Gene Lab Corp (BGLC). Recent figures show that the company’s insiders hold 51.11% of shares. A total of 3 institutional investors hold shares in the company, making 0.88% of its stock and 1.80% of its float.
Mar 31, 2025 , it was reported that the Company’s largest institutional holder is Citadel Advisors Llc holding total of 9.88 shares that make 0.55% of the company’s total number of shares and are currently priced at 0.12 million.
The securities firm Two Sigma Investments, LP holds 3.55 shares of BGLC, making it the second largest institutional shareholder. Taking this into account, the holding percentage comes to 0.20% , and the holding percentage of shares is valued at 41392.0.
An overview of BioNexus Gene Lab Corp’s technicals
In order to learn about trade movements and investor behavior, it is best to analyze the short, medium, and long term technical indicators along with the average volume of a stock. A 20-day average of the stock’s daily volume suggests BioNexus Gene Lab Corp (BGLC) traded 1,736,783 shares per day, with a moving average of $3.51 and price change of +10.41. With the moving average of $3.19 and a price change of +11.38, about 769,203 shares changed hands on average over the past 50 days. Finally, BGLC’s 100-day average volume is 763,743 shares, alongside a moving average of $3.18 and a price change of +10.30.
